 | • レポートコード：MRC2303B030 • 出版社/出版日：Mordor Intelligence / 2023年3月 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の市場調査書では、世界の着床前診断（PGT）市場規模が予測期間中に年平均10.5％上昇すると推測されています。本調査書では、着床前診断（PGT）の世界市場を広く調査・分析をし、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、診断種類別（着床前遺伝子診断（PGD）、着床前遺伝子スクリーニング（PGS））分析、製品・サービス別（器具、試薬・消耗品、ソフトウェア・サービス）分析、用途別（HLAタイピング、体外受精予後、異数性スクリーニング、その他）分析、エンドユーザー別（病院・診断研究所、マタニティセンター・不妊治療クリニック、その他）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来動向などを整理しています。また、本書には、The Cooper Companies Inc.、Illumina Inc.、Thermo Fisher Scientific Inc.、Quest Diagnostics Inc.、PerkinElmer Inc.、Invitae Corp.、Natera Inc.、Igenomix Sl、Bioarray SL、Genea Ltdなどの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の着床前診断（PGT）市場規模：診断種類別 - 着床前遺伝子診断（PGD）の市場規模 - 着床前遺伝子スクリーニング（PGS）の市場規模 ・世界の着床前診断（PGT）市場規模：製品・サービス別 - 器具の市場規模 - 試薬・消耗品の市場規模 - ソフトウェア・サービスの市場規模 ・世界の着床前診断（PGT）市場規模：用途別 - HLAタイピングにおける市場規模 - 体外受精予後における市場規模 - 異数性スクリーニングにおける市場規模 - その他用途における市場規模 ・世界の着床前診断（PGT）市場規模：エンドユーザー別 - 病院・診断研究所における市場規模 - マタニティセンター・不妊治療クリニックにおける市場規模 - その他エンドユーザーにおける市場規模 ・世界の着床前診断（PGT）市場規模：地域別 - 北米の着床前診断（PGT）市場規模 アメリカの着床前診断（PGT）市場規模 カナダの着床前診断（PGT）市場規模 メキシコの着床前診断（PGT）市場規模 … - ヨーロッパの着床前診断（PGT）市場規模 ドイツの着床前診断（PGT）市場規模 イギリスの着床前診断（PGT）市場規模 フランスの着床前診断（PGT）市場規模 … - アジア太平洋の着床前診断（PGT）市場規模 中国の着床前診断（PGT）市場規模 日本の着床前診断（PGT）市場規模 インドの着床前診断（PGT）市場規模 … - 南米/中東の着床前診断（PGT）市場規模 南アフリカの着床前診断（PGT）市場規模 ブラジルの着床前診断（PGT）市場規模 アルゼンチンの着床前診断（PGT）市場規模 … ・競争状況 ・市場機会・将来動向 |
The preimplantation genetic testing market studied was anticipated to grow with a CAGR of 10.5% during the forecast period.
During COVID-19, there was an increasing adoption of the preimplantation of genetic testing, which is expected to drive the market’s growth. The NCBI article published in October 2021 mentioned preimplantation genetic testing and embryologist specialization provided safety and assisted reproduction process have not negatively impacted patients with a previous record of COVID-19 infection. However, according to another NCBI article published in September 2022, women with COVID-19 during Pregnancy might have a higher risk of obstetrical and neonatal complications. Such risk of pre-natal complications in the infected patients boosted the demand for preimplantation genetic testing during the pandemic. Thus, the COVID-19 pandemic has increased the market’s growth, which is expected to follow the same traction during the forecast period of the study.
The primary factor attributing to the market’s growth is a rising awareness among parents regarding advancements in diagnostics, with a massive volume of neonatal deaths due to complications during childbirth. The growing prevalence of congenital genetic diseases like Edwards syndrome and common pediatric respiratory disorders such as pneumonia and asthma has been observed in recent years. As per the NCBI article published in August 2021, the in-facility birth prevalence rate for congenital abnormalities in South Africa was 15.57 per 1,000 live births. Another NCBI published in September 2022 states that the live birth prevalence with Edwards syndrome in the UK ranges from 1 in 3600 to 1 in 10,000. These abnormalities occur almost exclusively in couples with hereditary disorders, which were observed to occur majorly in industrialized nations. Thus, increased demand for earlier diagnosis and government initiatives to control the healthcare burden will likely drive the preimplantation genetic testing market.
Additionally, the increasing product launches by various market players are expected to boost market growth over the forecast period. For instance, Eurofins Genoma launched the niPGT-A, a non-non-invasive, in September 2022. It is an embryo biopsy-free, preimplantation genetic aneuploidy screening test. It provides IVF centers with access to a highly accurate alternative to traditional PGT-A testing.
Thus, the factors such as the growing prevalence of congenital genetic diseases and increasing product launches are expected to contribute to the market’s growth over the forecast period. However, the small size of the study population and ethical concerns, costly testing procedures, and unfavorable regulatory framework and challenges during the development stage may restrain the market’s growth over the forecast period.
Preimplantation Genetic Testing Market Trends
IVF Prognosis is Expected to Hold a Significant Market Share in the Preimplantation Genetic Testing Market Over the Forecast Period
Invitro fertilization(IVF) is a method of assisted reproduction and treatment for specific genetic and fertility issues. The prognosis for IVF is a necessary procedure to inspect the medical condition of the embryos by preimplantation genetic testing methods. Thus, preimplantation genetic testing plays a crucial role in the IVF prognosis, thereby contributing to the growth of the studied segment. The IVF prognosis segment is expected to account for a significant share of the preimplantation genetic testing market. It is mainly due to the high number of invitro fertilization procedures owing to the increased demand for preimplantation genetic testing procedures.
For instance, according to the MayoClinic article updated in May 2022, globally, 10–12% of couples have difficulty conceiving, which is expected to increase gradually in the coming years. IVF accounts for 1.6% and 4.5% of all US and Europe live births, respectively. Also, the same article quoted that approximately 25% to 35% of infertile women have a subperitoneal disease. Pelvic inflammatory disease (PID) is the most common cause of infertility, and poor semen quality in men is the sole cause of infertility in 20% of couples. Such a high burden of people having difficulty conceiving and a decrease in fertility rates contributes to the segment’s growth.
Additionally, the rising product launches by various market players are expected to drive the growth of the studied segment over the forecast period. For instance, in July 2022, GenEmbryonics launched the commercial whole genome sequencing test for effectively screening all genetic diseases in IVF embryos. This comprehensive testing clarifies the embryo’s genome sequence, allowing disease-causing mutations to be identified and screened.
Thus, factors such as rising infertility, increasing preference for IVF procedures, and growing product launches for IVF prognosis are expected to drive the growth of the studied segment over the forecast period.
North America is Expected to Hold a Significant Share in the Preimplantation Genetic Testing Market Over the Forecast Period
North America is expected to dominate the preimplantation genetic testing market. The dominance is due to a growing volume of cases of chromosome abnormality leading to various genetic disorders. Additionally, the increasing consumer awareness and the presence of significant market players in this region are also driving factors for the growth of the market in this region.
According to the Centers for Disease Control and Prevention (CDC) report in April 2021, about 6,000 babies born in the US have down syndrome every year. Similarly, the Province of British Columbia, Canada, an article published in February 2021, mentioned that in Canada, one in every 750 live babies born has Down syndrome. Additionally, the data published in Facets Journal in November 2021 noted that rare diseases affect approximately 1 in 12 Canadians, and most have underlying genetic causes. It, in turn, resulted in high demand for earlier diagnoses to identify the genetic defects in embryos, thus driving the market in the region.
The increasing market player’s activities, such as partnerships, mergers, and collaborations in North America to develop products, are also expected to contribute to the market’s growth. For instance, in October 2022, Ovation Fertility partnered with Genomic Prediction to license the LifeView PGT platform for genetic testing. This Lifeview PGT provides the most comprehensive currently available genetic test of the preimplantation embryo.
Thus, the high burden of genetic diseases and increasing market players’ activities, coupled with the rising awareness regarding preimplantation genetic testing in North American countries, is expected to drive the market’s growth in this region over the forecast period.
Preimplantation Genetic Testing Market Competitor Analysis
The preimplantation genetic testing market is moderately competitive and consists of several major players. Few of the key players dominating the market are following various strategies like an increased focus on R&D and launching new products. Some of the major companies currently dominating the market are The Cooper Companies Inc., Illumina Inc., Thermo Fisher Scientific Inc., PerkinElmer Inc., and Bioarray SL.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Burden of Genetic Diseases Like Patau Syndrome, Edwards Syndrome, and Down Syndrome
4.2.2 Increased Government Initiatives to Create Awareness and R&D Activities to Develop Advanced Diagnostic Devices
4.3 Market Restraints
4.3.1 Small Size of Study Population and Ethical Concerns
4.3.2 Highly Expensive Testing Procedures
4.3.3 Unfavorable Regulatory Framework and Challenges During Development Stage
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Test Type
5.1.1 Preimplantation Genetic Diagnosis (PGD)
5.1.2 Preimplantation Genetic Screening (PGS)
5.2 By Product and Service
5.2.1 Instruments
5.2.2 Reagents and Consumables
5.2.3 Software and Services
5.3 By Application
5.3.1 HLA Typing
5.3.2 IVF Prognosis
5.3.3 Aneuploidy Screening
5.3.4 Other Applications
5.4 By End User
5.4.1 Hospitals and Diagnostic Labs
5.4.2 Maternity Centers and Fertility Clinics
5.4.3 Other End Users
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 The Cooper Companies Inc.
6.1.2 Illumina Inc.
6.1.3 Thermo Fisher Scientific Inc.
6.1.4 Quest Diagnostics Inc.
6.1.5 PerkinElmer Inc.
6.1.6 Invitae Corp.
6.1.7 Natera Inc.
6.1.8 Igenomix Sl
6.1.9 Bioarray SL
6.1.10 Genea Ltd
7 MARKET OPPORTUNITIES AND FUTURE TRENDS